Financial Hardship—an Unwanted Consequence of Cancer Treatment

Julie McNulty, Nandita D Khera

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The substantial economic burden of cancer is increasingly being shifted to patients. Financial burden experienced by patients as a result of medical treatment has an impact on their lifestyle choices, health behaviors, and quality of life. Variation in treatment recommendations based on the patients’ economic status or affordability may be against the basic tenet of social justice and is a growing challenge for policy makers. This review summarizes the multifaceted constructs and current trends associated with financial hardship within the context of cancer care and healthcare economics focusing mainly on hematological malignancies but supplemented by nonhematological cancer and general medical literature. We also highlight the patient and physician perspectives about this issue and identify important areas for future research. We discuss the need for more proactive solutions so that patients can achieve good clinical outcomes, without catastrophic financial consequences for themselves and their families.

Original languageEnglish (US)
Pages (from-to)205-212
Number of pages8
JournalCurrent Hematologic Malignancy Reports
Volume10
Issue number3
DOIs
StatePublished - Jun 26 2015

Fingerprint

Economics
Neoplasms
Choice Behavior
Therapeutics
Health Behavior
Social Justice
Hematologic Neoplasms
Administrative Personnel
Life Style
Quality of Life
Delivery of Health Care
Physicians

Keywords

  • Cancer
  • Financial burden
  • Financial toxicity
  • Leukemia
  • Lymphoma
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Financial Hardship—an Unwanted Consequence of Cancer Treatment. / McNulty, Julie; Khera, Nandita D.

In: Current Hematologic Malignancy Reports, Vol. 10, No. 3, 26.06.2015, p. 205-212.

Research output: Contribution to journalArticle

@article{095654433fd84df39da02df9036a4d28,
title = "Financial Hardship—an Unwanted Consequence of Cancer Treatment",
abstract = "The substantial economic burden of cancer is increasingly being shifted to patients. Financial burden experienced by patients as a result of medical treatment has an impact on their lifestyle choices, health behaviors, and quality of life. Variation in treatment recommendations based on the patients’ economic status or affordability may be against the basic tenet of social justice and is a growing challenge for policy makers. This review summarizes the multifaceted constructs and current trends associated with financial hardship within the context of cancer care and healthcare economics focusing mainly on hematological malignancies but supplemented by nonhematological cancer and general medical literature. We also highlight the patient and physician perspectives about this issue and identify important areas for future research. We discuss the need for more proactive solutions so that patients can achieve good clinical outcomes, without catastrophic financial consequences for themselves and their families.",
keywords = "Cancer, Financial burden, Financial toxicity, Leukemia, Lymphoma, Multiple myeloma",
author = "Julie McNulty and Khera, {Nandita D}",
year = "2015",
month = "6",
day = "26",
doi = "10.1007/s11899-015-0266-1",
language = "English (US)",
volume = "10",
pages = "205--212",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Financial Hardship—an Unwanted Consequence of Cancer Treatment

AU - McNulty, Julie

AU - Khera, Nandita D

PY - 2015/6/26

Y1 - 2015/6/26

N2 - The substantial economic burden of cancer is increasingly being shifted to patients. Financial burden experienced by patients as a result of medical treatment has an impact on their lifestyle choices, health behaviors, and quality of life. Variation in treatment recommendations based on the patients’ economic status or affordability may be against the basic tenet of social justice and is a growing challenge for policy makers. This review summarizes the multifaceted constructs and current trends associated with financial hardship within the context of cancer care and healthcare economics focusing mainly on hematological malignancies but supplemented by nonhematological cancer and general medical literature. We also highlight the patient and physician perspectives about this issue and identify important areas for future research. We discuss the need for more proactive solutions so that patients can achieve good clinical outcomes, without catastrophic financial consequences for themselves and their families.

AB - The substantial economic burden of cancer is increasingly being shifted to patients. Financial burden experienced by patients as a result of medical treatment has an impact on their lifestyle choices, health behaviors, and quality of life. Variation in treatment recommendations based on the patients’ economic status or affordability may be against the basic tenet of social justice and is a growing challenge for policy makers. This review summarizes the multifaceted constructs and current trends associated with financial hardship within the context of cancer care and healthcare economics focusing mainly on hematological malignancies but supplemented by nonhematological cancer and general medical literature. We also highlight the patient and physician perspectives about this issue and identify important areas for future research. We discuss the need for more proactive solutions so that patients can achieve good clinical outcomes, without catastrophic financial consequences for themselves and their families.

KW - Cancer

KW - Financial burden

KW - Financial toxicity

KW - Leukemia

KW - Lymphoma

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=84941731246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941731246&partnerID=8YFLogxK

U2 - 10.1007/s11899-015-0266-1

DO - 10.1007/s11899-015-0266-1

M3 - Article

C2 - 26112652

AN - SCOPUS:84941731246

VL - 10

SP - 205

EP - 212

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 3

ER -